Antiinfectives targeting enzymes and the proton motive force

Xinxin Feng, Wei Zhu, Lici A. Schurig-Briccio, Steffen Lindert, Carolyn Shoen, Reese Hitchings, Jikun Li, Yang Wang, Noman Baig, Tianhui Zhou, Boo Kyung Kim, Dean C. Crick, Michael Cynamon, J. Andrew McCammon, Robert B. Gennis, Eric Oldfield

Research output: Contribution to journalArticle

Abstract

There is a growing need for new antibiotics. Compounds that target the proton motive force (PMF), uncouplers, represent one possible class of compounds that might be developed because they are already used to treat parasitic infections, and there is interest in their use for the treatment of other diseases, such as diabetes. Here, we tested a series of compounds, most with known antiinfective activity, for uncoupler activity. Many cationic amphiphiles tested positive, and some targeted isoprenoid biosynthesis or affected lipid bilayer structure. As an example, we found that clomiphene, a recently discovered undecaprenyl diphosphate synthase inhibitor active against Staphylococcus aureus, is an uncoupler. Using in silico screening, we then found that the anti-glioblastoma multiforme drug lead vacquinol is an inhibitor of Mycobacterium tuberculosis tuberculosinyl adenosine synthase, as well as being an uncoupler. Because vacquinol is also an inhibitor of M. tuberculosis cell growth, we used similarity searches based on the vacquinol structure, finding analogs with potent (∼0.5-2 μg/mL) activity against M. tuberculosis and S. aureus. Our results give a logical explanation of the observation that most new tuberculosis drug leads discovered by phenotypic screens and genome sequencing are highly lipophilic (logP ∼5.7) bases with membrane targets because such species are expected to partition into hydrophobic membranes, inhibiting membrane proteins, in addition to collapsing the PMF. This multiple targeting is expected to be of importance in overcoming the development of drug resistance because targeting membrane physical properties is expected to be less susceptible to the development of resistance.

Original languageEnglish (US)
Pages (from-to)E7073-E7082
JournalProceedings of the National Academy of Sciences of the United States of America
Volume112
Issue number51
DOIs
StatePublished - Dec 22 2015

Fingerprint

Proton-Motive Force
Mycobacterium tuberculosis
undecaprenyl pyrophosphate synthetase
Membranes
Staphylococcus aureus
Enzymes
Clomiphene
Parasitic Diseases
Terpenes
Lipid Bilayers
Glioblastoma
Drug Resistance
Pharmaceutical Preparations
Computer Simulation
Adenosine
Membrane Proteins
Tuberculosis
Genome
Anti-Bacterial Agents
Growth

Keywords

  • Bedaquiline
  • Clofazimine
  • Clomiphene
  • Molecular dynamics simulations
  • Vacquinol

ASJC Scopus subject areas

  • General

Cite this

Antiinfectives targeting enzymes and the proton motive force. / Feng, Xinxin; Zhu, Wei; Schurig-Briccio, Lici A.; Lindert, Steffen; Shoen, Carolyn; Hitchings, Reese; Li, Jikun; Wang, Yang; Baig, Noman; Zhou, Tianhui; Kim, Boo Kyung; Crick, Dean C.; Cynamon, Michael; McCammon, J. Andrew; Gennis, Robert B.; Oldfield, Eric.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 112, No. 51, 22.12.2015, p. E7073-E7082.

Research output: Contribution to journalArticle

Feng, X, Zhu, W, Schurig-Briccio, LA, Lindert, S, Shoen, C, Hitchings, R, Li, J, Wang, Y, Baig, N, Zhou, T, Kim, BK, Crick, DC, Cynamon, M, McCammon, JA, Gennis, RB & Oldfield, E 2015, 'Antiinfectives targeting enzymes and the proton motive force', Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 51, pp. E7073-E7082. https://doi.org/10.1073/pnas.1521988112
Feng, Xinxin ; Zhu, Wei ; Schurig-Briccio, Lici A. ; Lindert, Steffen ; Shoen, Carolyn ; Hitchings, Reese ; Li, Jikun ; Wang, Yang ; Baig, Noman ; Zhou, Tianhui ; Kim, Boo Kyung ; Crick, Dean C. ; Cynamon, Michael ; McCammon, J. Andrew ; Gennis, Robert B. ; Oldfield, Eric. / Antiinfectives targeting enzymes and the proton motive force. In: Proceedings of the National Academy of Sciences of the United States of America. 2015 ; Vol. 112, No. 51. pp. E7073-E7082.
@article{181f0c6f580e47b5b9c86a8a97d5997a,
title = "Antiinfectives targeting enzymes and the proton motive force",
abstract = "There is a growing need for new antibiotics. Compounds that target the proton motive force (PMF), uncouplers, represent one possible class of compounds that might be developed because they are already used to treat parasitic infections, and there is interest in their use for the treatment of other diseases, such as diabetes. Here, we tested a series of compounds, most with known antiinfective activity, for uncoupler activity. Many cationic amphiphiles tested positive, and some targeted isoprenoid biosynthesis or affected lipid bilayer structure. As an example, we found that clomiphene, a recently discovered undecaprenyl diphosphate synthase inhibitor active against Staphylococcus aureus, is an uncoupler. Using in silico screening, we then found that the anti-glioblastoma multiforme drug lead vacquinol is an inhibitor of Mycobacterium tuberculosis tuberculosinyl adenosine synthase, as well as being an uncoupler. Because vacquinol is also an inhibitor of M. tuberculosis cell growth, we used similarity searches based on the vacquinol structure, finding analogs with potent (∼0.5-2 μg/mL) activity against M. tuberculosis and S. aureus. Our results give a logical explanation of the observation that most new tuberculosis drug leads discovered by phenotypic screens and genome sequencing are highly lipophilic (logP ∼5.7) bases with membrane targets because such species are expected to partition into hydrophobic membranes, inhibiting membrane proteins, in addition to collapsing the PMF. This multiple targeting is expected to be of importance in overcoming the development of drug resistance because targeting membrane physical properties is expected to be less susceptible to the development of resistance.",
keywords = "Bedaquiline, Clofazimine, Clomiphene, Molecular dynamics simulations, Vacquinol",
author = "Xinxin Feng and Wei Zhu and Schurig-Briccio, {Lici A.} and Steffen Lindert and Carolyn Shoen and Reese Hitchings and Jikun Li and Yang Wang and Noman Baig and Tianhui Zhou and Kim, {Boo Kyung} and Crick, {Dean C.} and Michael Cynamon and McCammon, {J. Andrew} and Gennis, {Robert B.} and Eric Oldfield",
year = "2015",
month = "12",
day = "22",
doi = "10.1073/pnas.1521988112",
language = "English (US)",
volume = "112",
pages = "E7073--E7082",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
publisher = "National Academy of Sciences",
number = "51",

}

TY - JOUR

T1 - Antiinfectives targeting enzymes and the proton motive force

AU - Feng, Xinxin

AU - Zhu, Wei

AU - Schurig-Briccio, Lici A.

AU - Lindert, Steffen

AU - Shoen, Carolyn

AU - Hitchings, Reese

AU - Li, Jikun

AU - Wang, Yang

AU - Baig, Noman

AU - Zhou, Tianhui

AU - Kim, Boo Kyung

AU - Crick, Dean C.

AU - Cynamon, Michael

AU - McCammon, J. Andrew

AU - Gennis, Robert B.

AU - Oldfield, Eric

PY - 2015/12/22

Y1 - 2015/12/22

N2 - There is a growing need for new antibiotics. Compounds that target the proton motive force (PMF), uncouplers, represent one possible class of compounds that might be developed because they are already used to treat parasitic infections, and there is interest in their use for the treatment of other diseases, such as diabetes. Here, we tested a series of compounds, most with known antiinfective activity, for uncoupler activity. Many cationic amphiphiles tested positive, and some targeted isoprenoid biosynthesis or affected lipid bilayer structure. As an example, we found that clomiphene, a recently discovered undecaprenyl diphosphate synthase inhibitor active against Staphylococcus aureus, is an uncoupler. Using in silico screening, we then found that the anti-glioblastoma multiforme drug lead vacquinol is an inhibitor of Mycobacterium tuberculosis tuberculosinyl adenosine synthase, as well as being an uncoupler. Because vacquinol is also an inhibitor of M. tuberculosis cell growth, we used similarity searches based on the vacquinol structure, finding analogs with potent (∼0.5-2 μg/mL) activity against M. tuberculosis and S. aureus. Our results give a logical explanation of the observation that most new tuberculosis drug leads discovered by phenotypic screens and genome sequencing are highly lipophilic (logP ∼5.7) bases with membrane targets because such species are expected to partition into hydrophobic membranes, inhibiting membrane proteins, in addition to collapsing the PMF. This multiple targeting is expected to be of importance in overcoming the development of drug resistance because targeting membrane physical properties is expected to be less susceptible to the development of resistance.

AB - There is a growing need for new antibiotics. Compounds that target the proton motive force (PMF), uncouplers, represent one possible class of compounds that might be developed because they are already used to treat parasitic infections, and there is interest in their use for the treatment of other diseases, such as diabetes. Here, we tested a series of compounds, most with known antiinfective activity, for uncoupler activity. Many cationic amphiphiles tested positive, and some targeted isoprenoid biosynthesis or affected lipid bilayer structure. As an example, we found that clomiphene, a recently discovered undecaprenyl diphosphate synthase inhibitor active against Staphylococcus aureus, is an uncoupler. Using in silico screening, we then found that the anti-glioblastoma multiforme drug lead vacquinol is an inhibitor of Mycobacterium tuberculosis tuberculosinyl adenosine synthase, as well as being an uncoupler. Because vacquinol is also an inhibitor of M. tuberculosis cell growth, we used similarity searches based on the vacquinol structure, finding analogs with potent (∼0.5-2 μg/mL) activity against M. tuberculosis and S. aureus. Our results give a logical explanation of the observation that most new tuberculosis drug leads discovered by phenotypic screens and genome sequencing are highly lipophilic (logP ∼5.7) bases with membrane targets because such species are expected to partition into hydrophobic membranes, inhibiting membrane proteins, in addition to collapsing the PMF. This multiple targeting is expected to be of importance in overcoming the development of drug resistance because targeting membrane physical properties is expected to be less susceptible to the development of resistance.

KW - Bedaquiline

KW - Clofazimine

KW - Clomiphene

KW - Molecular dynamics simulations

KW - Vacquinol

UR - http://www.scopus.com/inward/record.url?scp=84952671080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952671080&partnerID=8YFLogxK

U2 - 10.1073/pnas.1521988112

DO - 10.1073/pnas.1521988112

M3 - Article

C2 - 26644565

AN - SCOPUS:84952671080

VL - 112

SP - E7073-E7082

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 51

ER -